Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rare tumor chemotherapy showdown: platinum vs. Non-Platinum

NCT ID NCT04365023

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study analyzed data from 168 patients with a rare type of digestive neuroendocrine tumor (well-differentiated grade 3). Researchers compared survival and response rates in patients who received platinum-based chemotherapy versus those who received non-platinum chemotherapy. The goal was to see which approach might work better for these uncommon tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
platinum chemotherapy
What this could lead to
If successful, this could help doctors choose better first-line chemotherapy for patients with these rare tumors, potentially improving survival.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove one treatment is better. The tumors are rare, making findings less generalizable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

168 people

The number who actually took part.

Started

Jul 2020

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

digestive tumors recorded in the national registry of endocrine tumors (GTE) and the TENpath registry

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Well-differentiated grade 3 neuroendocrine digestive tumors * Patient of 18 years old and more Exclusion Criteria: * Patient opposed to data collection as part of the study * Digestive neuroendocrine tumors Grade 1-2 * Grade 3 poorly differentiated digestive neuroendocrine tumors * Malignant disease diagnosed in the last 5 years (except basal cell of the skin and in situ cervical carcinoma) * Other non-digestive neuroendocrine tumors * Mixed neuroendocrine non neuroendocrine neoplasm

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine tumor, grade 1/2 neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine tumors

Contacts and locations

Locations

  • Gastroenterology and digestive oncology unit - Cochin hospital

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.